Protection against SIV infection in macaques by immunization with inactivated virus from the BK28 molecular clone, but not with BK28‐derived recombinant env and gag proteins
| Autor: | K.H.G. Mills, M. Page, W.L. Chan, P. Kitchin, E.J. Stott, F. Taffs, W. Jones, J. Rose, C. Ling, P. Silvera, T. Corcoran, B. Flanagan, A. Burny, F. Bex, M. Delchambre, O. Van Opstal, L. Fabry, C. Thiriart, A. Delers, M. DeWilde, C. Bruck |
|---|---|
| Rok vydání: | 1992 |
| Předmět: |
Cellular immunity
General Veterinary animal diseases viruses medicine.medical_treatment virus diseases Simian immunodeficiency virus Biology medicine.disease_cause Virology Virus Microbiology law.invention Immune system law Humoral immunity medicine biology.protein Recombinant DNA Animal Science and Zoology Antibody Adjuvant |
| Zdroj: | Journal of Medical Primatology. 21:50-58 |
| ISSN: | 1600-0684 0047-2565 |
| DOI: | 10.1111/j.1600-0684.1992.tb00567.x |
| Popis: | Vaccination of cynomolgus macaques with beta-propiolactone inactivated SIVmacBK28 in Freund's adjuvant induced low but detectable levels of anti-SIV envelope (env) antibodies and T-cell responses and protected against challenge with the 32H isolate of SIVmac251 grown in C8166 cells. In contrast, purified recombinant SIV env and gag proteins derived from BK28 formulated in Syntex adjuvant generated consistent and long-lived cellular and humoral immune responses to SIV env, but failed to protect against infection with the 32H virus. Thus, protection against a heterogeneous challenge stock is possible by immunization with a molecularly-cloned virus, but not with recombinant proteins from the same molecular origin. High levels of anti-cell antibodies induced by the whole virus vaccine, but not by recombinant proteins, may have contributed to the protection observed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|